하이 로우 토토 사이트

In March, South Korea’s biotech sector surged with breakthroughs from companies like HLB and Alteogen. 하이 로우 토토 사이트 is set to continue that momentum, starting with Bridge Biotherapeutics' long-awaited Phase 2 data. Additional milestones—ranging from early-stage clinical results to high-profile IPOs—promise to shape the industry landscape. Below are the major developments to watch this month.

Bridge Biotherapeutics is expected to announce topline results from its global Phase 2 trial of BBT-877, a treatment for idiopathic pulmonary fibrosis (IPF), within 하이 로우 토토 사이트. The drug inhibits autotaxin (ATX), disrupting the lysophosphatidic acid (LPA) signaling pathway to suppress both inflammation and fibrosis progression. Unlike existing therapies that only slow the disease, BBT-877 aims to halt progression by targeting its root cause.

Developed independently after receiving FDA approval, the 하이 로우 토토 사이트 enrolled 129 patients across five countries—including the U.S., Korea, and Australia—with participants both on and off standard treatments (Ofev, Esbriet). The drug has shown a low rate of adverse events and sustained efficacy across groups, including those on background therapy. Multiple global pharmaceutical companies have already entered due diligence, setting the stage for potential licensing deals following data release.

Voronoi will present early Phase 1 data for its fourth-generation EGFR inhibitor VRN11 at the American Association for Cancer Research (AACR) 2025 meeting, beginning 하이 로우 토토 사이트 25. Designed to overcome resistance mutations like C797S and preserve wild-type EGFR, VRN11 boasts full blood-brain barrier penetration, selective inhibition, and strong preclinical safety.

The Phase 1 하이 로우 토토 사이트, which expanded from 50 to 103 participants, is testing doses up to 320 mg with the potential for further escalation. Targeting heavily pretreated patients, the 하이 로우 토토 사이트 aims to include treatment-naïve individuals in its next phase. The AACR presentation will serve as a springboard for evaluating Phase 2 potential and future licensing.

Meanwhile, S.Biomedics will share interim results from its Phase 1/2a trial of TED-A9, an embryonic stem cell-derived therapy for Parkinson’s disease, at the AD/PD 2025 meeting on 하이 로우 토토 사이트 5. One-year data from 12 patients will be presented, following promising initial results reported last November that indicated motor function improvement in the first six participants.

TED-A9 transplants midbrain-specific dopaminergic progenitor cells directly into the brain to restore neural circuits. This approach differs from conventional therapies by aiming to replace lost neurons, not just mimic dopamine signaling. As a rare Korean entry in the neurological regenerative medicine space, this 하이 로우 토토 사이트 may mark a pivotal moment for commercial prospects in cell therapy.

Beyond clinical outcomes, several key events are set to shape how the market evaluates biotech company valuations. As they prepare for IPOs, Korean biotech firms are emphasizing not just technological strength, but also commercialization strategies and pipeline visibility to attract investor confidence.

ImmuneOnciais scheduled to begin its public subscription period on 하이 로우 토토 사이트 14–15, aiming to list on the KOSDAQ with a cancer immunotherapy pipeline built around immune checkpoint inhibitors. A subsidiary of Yuhan Corporation, the company was founded in 2016 and is noted for having built its own antibody therapy CMC and preclinical research infrastructure from the early stages.

Its main pipeline includes PD-L1-targeting antibody IMC-001 and CD47-targeting antibody IMC-002. IMC-001 has completed a Phase 2 하이 로우 토토 사이트 in South Korea for NK/T-cell lymphoma, a rare blood cancer, and is now preparing a marketing application. It is considered rare for a company seeking listing under Korea’s technology-special listing system to have an immunotherapy candidate already supported by regulatory data, earning it recognition as a performance-based IPO strategy. IMC-002, an Fc-free CD47 antibody, is designed to overcome hemolytic toxicity seen in earlier drugs. It is currently in a Phase 1b combination 하이 로우 토토 사이트 for hepatocellular carcinoma (HCC) and triple-negative breast cancer (TNBC). In 2021, the company successfully licensed the drug to China’s 3D Medicines in a deal worth 0.5 million. Clinical entry in China is planned for next year, alongside renewed global licensing discussions.

Organoid Sciences, a regenerative medicine and drug toxicity testing platform company utilizing stem cell-derived organoids, is also moving forward with its KOSDAQ listing this 하이 로우 토토 사이트 through investor demand forecasting and subscription procedures.

While no organoid-based therapy has been commercialized in Korea yet, Organoid Sciences has developed a platform that extends beyond research tools to combine clinical applicability and revenue potential. Its key offerings include patient-derived cancer organoids for predicting drug responses and a chronic toxicity screening platform. These have already been applied in practice through joint studies with hospitals and research institutions. The IPO is drawing attention as a litmus test for how the market will evaluate platform-based biotech models.

ROKIT Healthcarewill pursue its KOSDAQ listing on 하이 로우 토토 사이트 15–16, led by its 3D bioprinting-based personalized skin regeneration therapy. Based on its securities filing on March 20, the company’s target IPO price range is .55 to .92, with the listing date yet to be finalized.

ROKIT’s core technology involves printing regenerative cell layers that closely mimic real skin tissue using patient-specific bioinks, which are then directly transplanted onto the affected area. The company is currently pursuing clinical 하이 로우 토토 사이트s and regulatory approval for chronic wound treatments, including diabetic foot ulcers and pressure sores. Alongside the novelty of its technology, the company's global supply chain and distribution strategy are expected to be key evaluation criteria.